Option Millionaires

[madrose1]

$MDVN price target raised to $134 from $119 at William Blair

MDVN target raised to $122 from $113 at Jefferies
Jefferies raised its price target for Medivation after Xtandi won FDA approval three months earlier than expected. The firm found the drug's label in-line with expectations and reiterates a Buy rating on the stock.

fridays , never a good time to short momo biotechs when FDA usually does their releases